fda compounding semaglutide news today The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the FDA Update: Current Guidelines for

*Correspondence: Jing Yao, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

The attorneys general identified the following concerns including: Counterfeit semaglutide imported from China, Turkey and India and repackaged as FDA-approved products Online sellers promoting research-only peptides while providing instructions for human injection Consumers mixing raw powders at home, leading to overdoses, contamination and serious adverse events Compounding pharmacies operating around legal boundaries, including insanitary conditions and high-impurity formulations Risks of hospitalization tied to dosing errors and adulterated ingredients The attorneys general asked the FDA and the Department of Homeland Security to take joint action to intercept illegal imports and protect patient safety

Easy to take, no jitters, and the sourcing is refreshingly transparent

Ok for nursing, not pregnancy though